RecruitingPhase 2NCT07172347
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Enrollment
120 participants
Start Date
Oct 31, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria2
- The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
- The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.
Exclusion Criteria5
- Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
- All hair in the vitiligo area on the face is white.
- Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.
- Subjects who have previously received depigmentation treatment.
- Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVC005 tablets
VC005 groups repeat administration for 52 weeks
DRUGVC005 Tablets Placebo
VC005 Placebo groups repeat administration for 52 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07172347
Related Trials
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT0743117715 locations
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
NCT072232293 locations
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
NCT072515951 location
Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients
NCT069919721 location
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
NCT071052541 location